Conference Coverage

Sputum microbiome may augur treatment success in NTM-PD


 

AT CHEST 2023

Promising start

A pulmonologist who was not involved in the study commented in an interview that, although the findings need further study, the microbiome of sputum samples has the potential for predictive value.

“I think this will be clinically useful, actually, if we’re able to identify and diagnose patients with MAC disease and then we identify their sputum microbiome, it might give us an idea whether these patients are more sensitive or refractory to treatment,” said Muhammad U. Khawar, MD, from the University of Cincinnati.

Dr. Khawar moderated the session where Dr. Kang reported her data.

The investigators did not report a funding source. Dr. Kang and Dr. Khawar reported that they had no relevant disclosures.

Pages

Recommended Reading

Minimally invasive surfactant shows some benefit in infants’ first 2 years
MDedge Family Medicine
Diagnosing progressive pulmonary fibrosis
MDedge Family Medicine
Paxlovid and Lagevrio benefit COVID outpatients in Omicron era
MDedge Family Medicine
Three antibiotic regimens show similar effectiveness for CAP
MDedge Family Medicine
Respiratory infections, asthma rise before type 2 diabetes
MDedge Family Medicine
Short, long-lasting bronchodilators similar for exacerbated COPD
MDedge Family Medicine
Paxlovid tied to benefits in high-risk patients with COVID
MDedge Family Medicine
Nintedanib dose reductions in IPF may do no harm
MDedge Family Medicine
Biologics linked to fewer hospitalizations after asthma exacerbation
MDedge Family Medicine
Pulmonary hypertension increases ARDS mortality risk
MDedge Family Medicine